Results 31 to 40 of about 3,523 (219)

CD4+ T cells are the major predictor of HCMV control in allogeneic stem cell transplant recipients on letermovir prophylaxis

Frontiers in Immunology, 2023
IntroductionHuman cytomegalovirus (HCMV) causes significant morbidity and mortality in allogeneic stem cell transplant (alloSCT) recipients. Recently, antiviral letermovir prophylaxis during the first 100 days after alloSCT replaced PCR-guided preemptive
Chris David Lauruschkat, Ihsan Muchsin, Alice Rein, Florian Erhard, Denise Grathwohl, Lars Dölken, Lars Dölken, Carolin Köchel, Christine Susanne Falk, Christine Susanne Falk, Christine Susanne Falk, Hermann Einsele, Sebastian Wurster, Götz Ulrich Grigoleit, Götz Ulrich Grigoleit, Sabrina Kraus   +15 more
doaj   +1 more source

Letermovir for Cytomegalovirus Prophylaxis in Lung Transplant Patients with Valganciclovir-Induced Leukopenia

Transplantology, 2021
Cytomegalovirus (CMV) prophylaxis with valganciclovir is the standard of practice in most transplant centers, but treatment-related leukopenia can limit valganciclovir’s use.
Arindam Singha, Pamela K. Burcham, April Logan, Zeinab El Boghdadly, Molly M. Howsare, David R. Nunley, Mark E. Lustberg, Brian C. Keller   +7 more
doaj   +1 more source

Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation. [PDF]

, 2020
Human cytomegalovirus (HCMV) can cause significant disease in immunocompromised patients, and treatment options are limited by toxicities. CSJ148 is a combination of two anti-HCMV human monoclonal antibodies (LJP538 and LJP539) that bind to and inhibit ...
Akard, Luke, Chemaly, Roy, Christoph, Sandra, Gerbitz, Armin, Hiemenz, John, Holler, Ernst, Hwang, William YK, Jang, Junho, Koh, Liang Piu, Lee, Dong-Gun, Logan, Aaron C, Long, Gwynn, Maertens, Johan, Mielke, Stephan, Pertel, Peter, Ramachandra, Sangana, Segal, Florencia, Smith, Kristin, Tang, Jih-Luh, Wang, Po-Nan, Winkler, Julia, Yeh, Su-Peng, Yeo, Adeline   +22 more
core   +3 more sources

Use of Letermovir for CMV Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation: Review of the Literature and Single-Center Real-Life Experience

Hemato, 2023
Cytomegalovirus (CMV) reactivation after allogeneic hematopoietic stem cell transplant (allo-HSCT) is mainly due to an increase of latent viremia in previously exposed patients.
Jessica Gill, Davide Stella, Irene Dogliotti, Chiara Dellacasa, Luisa Giaccone, Alessandro Busca   +5 more
doaj   +1 more source

Slaying the "Troll of Transplantation"-new frontiers in cytomegalovirus management. A report from the CMV International Symposium 2023 [PDF]

, 2023
: The 2023 International CMV Symposium took place in Barcelona in May 2023. During the 2-day meeting, delegates and faculty discussed the ongoing challenge of managing the risk of cytomegalovirus infection (the Troll of Transplantation) after solid organ
Kotton, Camille N, Malagola M, Torre-Cisneros, Julian, Yakoub-Agha, Ibrahim   +3 more
core   +1 more source

Congenital Cytomegalovirus Infection: A Narrative Review of the Issues in Screening and Management From a Panel of European Experts. [PDF]

, 2020
Maternal primary and non-primary cytomegalovirus (CMV) infection during pregnancy can result in in utero transmission to the developing fetus. Congenital CMV (cCMV) can result in significant morbidity, mortality or long-term sequelae, including ...
Blázquez-Gamero, D, Delforge, M-L, Foulon, I, Lazzarotto, T, Leruez-Ville, M, Luck, S, Modrow, S   +6 more
core   +1 more source

Immunity Risk Associated With Cytomegalovirus Infection After Organ Transplantation [PDF]

, 2023
Cytomegalovirus (CMV), a member of the Herpesviridae family, is frequently seen in hematopoietic cell transplant (HCT) and solid organ transplant (SOT) patients and is a major cause of morbidity and mortality in absence of antiviral prophylaxis in the ...
Bidisha Ghosh, Sahely Roy, Semanti Ghosh, Srijani Karmakar, Subhasis Sarkar, Suranjana Sarkar   +5 more
core   +3 more sources

Letermovir prophylaxis for cytomegalovirus reactivation in children who underwent hematopoietic stem cell transplantation: A single-institute experience in Taiwan

Journal of Microbiology, Immunology and Infection, 2022
From January 2019 to May 2021, 11 children underwent allogeneic stem cell transplantation at our institute. Four of them received letermovir for cytomegalovirus prophylaxis.
Chao-Neng Cheng, Sin-Syue Li, Yun-Hsuan Yeh, Ching-Fen Shen, Jiann-Shiuh Chen   +4 more
doaj   +1 more source

Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients

CPT: Pharmacometrics & Systems Pharmacology, 2021
Letermovir is indicated for prophylaxis of cytomegalovirus infection and disease in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Two‐stage population pharmacokinetic (PK) modeling of letermovir was conducted to support dose rationale ...
Marita Prohn, Anders Viberg, Da Zhang, Kevin Dykstra, Casey Davis, Sreeraj Macha, Philip Sabato, Dinesh deAlwis, Marian Iwamoto, Craig Fancourt, Carolyn R. Cho   +10 more
doaj   +1 more source

Clinical and Economic Burden of Cytomegalovirus (CMV) Infection/Disease Among Hospitalized Adult Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT) Recipients in China. [PDF]

J Med Virol
ABSTRACT Cytomegalovirus (CMV) infection is a prevalent complication among allogeneic hematopoietic stem cell transplant (allo‐HSCT) recipients, posing significantly impact on clinical outcomes and healthcare costs. This study aims to assess the clinical and economic burden of CMV infection in hospitalized adult allo‐HSCT recipients in China.
Yan C, Xia L, Lu X, Wang Y, Duan X, Wang X, Wang R, Huang J, Xu L, Zhang X, Huang X.   +10 more
europepmc   +2 more sources